WuXi Biologics (Cayman) Inc
WuXi Biologics (Cayman) Inc., an investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People's Republic of China, North America, Europe, Singapore, Japan, South Korea, and Australia. It operates through two segments: Biologics and XDC. The company provides a suite of solutions for biologic disc… Read more
Market Cap & Net Worth: WuXi Biologics (Cayman) Inc (WXXWY)
WuXi Biologics (Cayman) Inc (PINK:WXXWY) has a market capitalization of $11.66 Billion ($11.66 Billion) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #1177 globally and #906 in its home market, demonstrating a -15.85% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying WuXi Biologics (Cayman) Inc's stock price $5.68 by its total outstanding shares 2052885317 (2.05 Billion).
WuXi Biologics (Cayman) Inc Market Cap History: 2017 to 2025
WuXi Biologics (Cayman) Inc's market capitalization history from 2017 to 2025. Data shows growth from $11.55 Billion to $11.66 Billion (0.94% CAGR).
WuXi Biologics (Cayman) Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how WuXi Biologics (Cayman) Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.41x
WuXi Biologics (Cayman) Inc's market cap is 0.41 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
2.30x
WuXi Biologics (Cayman) Inc's market cap is 2.30 times its annual earnings
0.11x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $11.55 Billion | $1.62 Billion | $252.63 Million | 7.13x | 45.71x |
| 2018 | $12.88 Billion | $2.53 Billion | $630.59 Million | 5.08x | 20.43x |
| 2019 | $26.00 Billion | $3.98 Billion | $1.01 Billion | 6.53x | 25.64x |
| 2020 | $54.01 Billion | $5.61 Billion | $1.69 Billion | 9.62x | 31.98x |
| 2021 | $48.12 Billion | $10.29 Billion | $3.39 Billion | 4.68x | 14.20x |
| 2022 | $30.94 Billion | $15.27 Billion | $4.42 Billion | 2.03x | 7.00x |
| 2023 | $15.29 Billion | $17.03 Billion | $3.40 Billion | 0.90x | 4.50x |
| 2024 | $7.72 Billion | $18.68 Billion | $3.36 Billion | 0.41x | 2.30x |
Competitor Companies of WXXWY by Market Capitalization
Companies near WuXi Biologics (Cayman) Inc in the global market cap rankings as of March 18, 2026.
Key companies related to WuXi Biologics (Cayman) Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
WuXi Biologics (Cayman) Inc Historical Marketcap From 2017 to 2025
Between 2017 and today, WuXi Biologics (Cayman) Inc's market cap moved from $11.55 Billion to $ 11.66 Billion, with a yearly change of 0.94%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $11.66 Billion | +51.06% |
| 2024 | $7.72 Billion | -49.53% |
| 2023 | $15.29 Billion | -50.56% |
| 2022 | $30.94 Billion | -35.71% |
| 2021 | $48.12 Billion | -10.91% |
| 2020 | $54.01 Billion | +107.76% |
| 2019 | $26.00 Billion | +101.81% |
| 2018 | $12.88 Billion | +11.56% |
| 2017 | $11.55 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of WuXi Biologics (Cayman) Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $11.66 Billion USD |
| MoneyControl | $11.66 Billion USD |
| MarketWatch | $11.66 Billion USD |
| marketcap.company | $11.66 Billion USD |
| Reuters | $11.66 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.